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ABSTRACT 
Lymphomas are a group of cancers which originate from lymphatic cells. More than 90% of 
the lymphomas belong to the group of Non-Hodgkin lymphoma (NHL), which in itself is a 
non-homogeneous group consisting of different NHL subtypes. Traditionally, lymphomas are 
not thought of as hormone-related cancers. This is strange considering that epidemiological 
studies show a clear gender difference in incidence for most lymphomas with men being 
more affected and females showing a better prognosis when compared to males. The aim of 
this thesis was to study molecular mechanisms involved in this gender difference with a focus 
on sex hormones, particularly estrogens acting through estrogen receptor  (ER). 
Furthermore, since both survival and drug sensitivity of lymphomas can be affected by its 
microenvironment, we analyzed the impact of stromal cells on ibrutinib sensitivity of mantle 
cell lymphoma (MCL) and how stromal cell-mediated ibrutinib resistance can be overcome.  
Paper I. In this study, gender aspects and estrogen regulation of diffuse large B-cell 
lymphoma (DLBCL) was studied. When studying DLBCL in a xenograft mouse model, we 
observed a faster tumor growth in males than in females. Tumor growth was significantly 
inhibited when mice were treated with the ERβ agonist diarylpropionitrile (DPN). This was 
the case both for germinal center and activated B-cell like subtype DLBCL. In addition, when 
analyzing nuclear ERβ1 expression by immunohistochemistry in primary DLBCLs, ERβ1 
expression was found in 89% of the cases. No gender difference in ER1 expression was 
found. However, the association between ERβ1 expression and prognosis was complex and 
shown to be dependent on drug treatment. These results suggest that targeting estrogen 
signaling via ERβ1 could be a new approach in treating DLBCL. Furthermore, ERβ1 
expression might be used as a prognostic marker. 
Paper II. In this article, we showed that castration of C57BL6 male mice accelerated tumor 
growth of lymphoma in C57Bl6 mice engrafted with murine EG7 T cell lymphoma cells.  By 
analyzing the tumor tissue, we observed stronger Ki67 and weaker TUNEL staining in 
castrated mice, indicating increased proliferation and decreased apoptosis. Treatment of intact 
male mice with the androgen receptor antagonist Bicalutamide had no effect on lymphoma 
growth, suggesting that signaling via the androgen receptor is not involved in the enhanced 
EG7 lymphoma growth following castration. In contrast, accelerated lymphoma growth was 
observed when mice were treated with aromatase inhibitors (AIs), which inhibit androgen-to-
estrogen conversion. Similar effects where seen in mice grafted with human Granta-519 
MCL cells or when treated with different AIs. Moreover, dihydrotestosterone, which can’t be 
  
converted to estrogens by aromatase, did not have any impact of lymphoma growth in male 
mice. This further supported an indirect effect of androgens on lymphoma growth, which 
involves the conversion of endogenous testosterone to estrogens. We conclude that blocking 
estrogen synthesis may accelerate lymphomas growth, which highlights the protective role 
estrogens may have on lymphoma progression. Furthermore, our results may raise concern 
for increased lymphoma risk (at least progression) in breast cancer patients treated with AIs.  
Paper III. In this report we showed that MCL tumor growth derived from engrafted human 
MCL and Burkitt lymphoma (BL) cells was inhibited by treatment with selective agonists of 
ER. Using the selective ERagonist DPN, we in tumors derived from Granta-519 MCL 
cells also demonstrated reduced expression of BAFF and GRB7, two markers of B-cell 
proliferation and survival. In addition, DPN treatment inhibited the expression of VEGF-C, 
LYVE-1, CD34 and angiogenin, markers of angiogenesis and lymphangiogenesis. Moreover, 
by investigating Raji BL cells engrafted to mice, we found that DPN treatment reduced tumor 
dissemination. Importantly, ER protein expression was demonstrated in primary MCL 
specimens. These results support that lymphomas are under estrogen control and suggest that 
treatment with ER agonists may be a new approach in the treatment of at least some 
lymphoma subtypes. 
Paper IV. By using a MCL-stromal cell co-culture system, we demonstrate that stromal cells 
protect MCL from ibrutinib-induced apoptosis and support MCL cell regrowth after drug 
removal by impairing ibrutinib-mediated repression of phosphoinositide-3-kinase 
(PI3K)/AKT signaling. Importantly, the stromal cell-mediated ibrutinib resistance was 
overcome by inhibiting AKT activity using the PI3Kα specific inhibitor BYL719. Enhanced 
pro-apoptotic effect by combined ibrutinib plus BYL719 treatment was also observed in 
primary MCL cells when co-cultured with stromal cells. Moreover, the combined treatment 
with ibrutinib and BYL719 enhanced inhibition of MCL tumor growth in vivo in xenograft 
experiments. We found that a direct interaction between MCL cells and stromal cell 
conferred the ibrutinib resistance and that this involved the adhesion molecule VLA-4. 
Blocking VLA-4 abrogated the ibrutinib resistance as assayed in a cell apoptosis and a cell 
regrowth assay. Our results suggest that combined treatment with ibrutinib and a PI3Kα 
inhibitor, alternatively blocking VLA-4, may be a promising therapeutic strategy to overcome 
stromal cell-mediated ibrutinib resistance in MCL.  
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1 BACKGROUND  
1.1 LYMPHOMA  
Lymphoma is a cancer which derives from cells of the lymphoid system. Lymphoma is a 
heterogeneous group of cancer. Generally, lymphoma can be classified into Hodgkin 
lymphoma (HL) and Non-Hodgkin lymphoma (NHL) and they affect  both children and 
adults.
1
 NHL is more common than HL and accounts for about 90% of all the lymphomas. 
Generally, the incidence increases with age, especially for some NHL subtypes like diffuse 
large B-cell lymphoma (DLBCL) and Mantle cell lymphoma (MCL). Some other lymphomas 
like HL and NHL Burkitt lymphoma (BL) show a biphasic incidence with one peak 
appearing in children/adolescents and a second in adults/elderly.
2
 An alternative and more up-
to-date division of the various lymphomas and more clinically related is the classification 
based on the tumors growth characteristics into aggressive and indolent NHL, respectively. 
Follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) are considered as 
indolent lymphoma with the characteristic of slow growth but difficult to cure. In contrast, 
NHL such as DLBCL, BL and MCL are usually considered as aggressive lymphoma with 
characteristics of fast clinical progression but often more sensitive to intensive therapy, at 
least in the initial state. However, many of the aggressive lymphomas may relapse. This is 
e.g. the case with MCL, which is considered incurable. (http://www.cancer.net/cancer-
types/lymphoma-non-hodgkin/subtypes). The causes for lymphomas are unknown but some 
risk factors are high age, male gender, infection (e.g. by Epstein-Barr virus), autoimmune 
disease, immunosuppression, exposure to some chemicals (e.g. some solvents) and in rare 
cases heritage. 
1.2 NHL 
NHL occurs worldwide but is more common in developed countries and is the fifth most 
common cancer in USA (19 cases per 100 000), while in developing countries like Thailand 
and China, the reported rates are lower (2-3 cases per 100 000).
3
 NHL can be divided into B-
cell lymphoma and T-cell lymphoma based on which kind of precursor lymphocyte the 
lymphoma originates from. There are also some rare forms of NHL such as lymphomas from 
natural killer cells.
4
 Among NHL, B-cell lymphomas make up about 95% of all NHL, and 
their origin from different stages during the B cell differentiation process are generally well 
established.
5
 The different stages in the B cell maturation takes place mainly in three 
compartments, the pre-germinal center, germinal center and post-germinal center, 
respectively, and B-cell lymphomas can develop at any stage during the normal B cell 
 2 
development. Generally, Mantle cell lymphoma (MCL), Small lymphocytic leukemia (SLL) 
and Chronic lymphocytic leukemia (CLL) develop in pre-germinal center; Burkitt lymphoma 
(BL), Germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) and 
Follicular lymphoma (FL) develop in germinal center while activated B cell like diffuse large 
B-cell lymphoma (ABC-DLBCL) and Multiple myeloma (MM) develop in post-germinal 
center (Figure 1). Among the B-cell lymphomas, DLBCL is the most common subtype, 
accounting for 30-40% of the B-cell lymphomas. This is followed by FL 20%, CLL 7%, 
MCL 6% and BL 2%.
6
 
  
Figure 1: Overview of the stages of B-cell maturation and the association to the different B 
cell lymphomas 
6
 
1.3 DLBCL 
DLBCL is considered as an aggressive B-cell malignancy because of its fast growth. Another 
feature of DLBCL is the heterogeneity, with about 40% of DLBCL patients responding to 
chemotherapy very well, while the rest do not. Gene expression profiling has been introduced 
to distinguish between different DLBCL subtypes and three major molecularly different 
forms have been identified. The DLBCLs originating in the germinal center display gene 
expression patterns similar to germinal center B cell, while the DLBCLs derived in post-
germinal center are more like in vitro activated B cells.
7
 Based on the above features, DLBCL 
can be divided into GCB-DLBCL and ABC-DLBCL. In clinical trials, patients with GCB-
DLBCL have a better prognosis than those with ABC-DLBCL, and recently reported data 
indicate that a high constitutive NF-κB activity in ABC-DLBCL may contribute to this 
poorer prognosis.
7-9
 In addition, primary mediastinal B cell lymphoma (PMBL), a third 
subtype of DLBCL has also been identified based on the different gene expression profiling. 
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PMBL patients are usually younger and have a more favorable outcome compared with the 
other DLBCL patients.
10
 
1.4 MCL 
MCL is considered as an incurable B cell malignancy with poor prognosis, and accounts for 
approximately 6% of all cases of NHL. MCL occurs mainly in elderly population (median 
age 73.5 years old).
2
 MCL usually involves the bone marrow and can be also found in 
peripheral blood (leukemic spread).
11
 MCL express CD5, CD19, CD20, CD22, but lack 
CD23 expression.
12,13
 It is characterized by the t(11;14)(q13;q32) translocation, which results 
in ectopical Cyclin D1 (CCND1) expression.
14
 The t(11;14)(q13;q32) translocation 
juxtaposes CCND1 at 11q13 to the 14q32, where the immunoglobulin heavy chain complex 
(IGH) is located. This is considered as the primary event of MCL development. CCND1 
overexpression causes a G1/S phase transition, thereby accelerating MCL growth. However, 
CCND1 overexpression is not sufficient for development of MCL.
15
 Apart from the 
dysregulation of the cell cycle, cell survival signaling pathway activation and change of DNA 
damage response also contribute to the MCL development.
15,16
 After the t(11;14)(q13;q32) 
translocation in the bone marrow, cells move to the peripheral lymphoid organs like lymph 
nodes, where most of them locate in the mantle zones without entering into the germinal 
center.
17
 However, recently it has also been found that 15% to 40% of MCLs carry IGHV 
hyper-mutations, suggesting that these MCLs move into the germinal center. This 
observation displays a more complex scenario in the classification of different subtypes of 
MCLs.
18,19
 In addition, CCND1 negative MCL cases have also been identified, which showed 
similar clinical characteristics and gene expression profiling as CCND1 positive MCL. Apart 
from CCND1, new MCL markers are now being used to distinguish between MCL and other 
B cell malignancies. Lymphoid enhancer-binding factor 1 is usually negative in MCLs while 
SOX11 is positive in most MCL cases. It has been reported that SOX11 aberrant expression 
contributes to the classical MCL pathogenesis while SOX11 is absent in lymphoid 
progenitors and mature B cell lymphomas.
20,21
    
1.5 GENDER, SEX HORMONES AND NHL RISK 
1.5.1 Gender difference of NHL 
It is reported that NHL is about 30% to 50% more common in men compared to women.
3,22,23
 
This includes DLBCL, the most common NHL subtype, which shows a M/F incidence ratio 
of 1.2 to 1.6:1 in patients of the age of 50 to 85 years.
24,25
 Interestingly, among different 
NHLs, the M/F ratio vary a lot, for instance MCL have a very high M/F incidence ratio (2-
 4 
7:1), while the second most common subtype, FL, shows no incidence difference between 
genders.
11,25
 Not only has a gender bias been observed in B-cell malignancies, but also in 
peripheral T-cell derived lymphomas, with a M/F incidence ratio of 1.8:1.
26
 Moreover, from a 
recent Swedish population based study of DLBCL, male gender was found to be an adverse 
risk factor for patients less than 52 years of age. For females in the same age group, survival 
rate was higher, but this difference disappears after menopause.
27
 Based on this and other 
epidemiological data, it is not unlikely that the gender difference in lymphoma incidence 
could be related to sex hormones, suggesting that lymphoma could be a sex hormone-related 
cancer.  
1.5.2 Sex hormones and NHL risk 
In line with the above epidemiological studies, indicating a role of sex hormone in lymphoma 
development, it has further been reported that reproductive factors and exogenous hormone 
exposure is associated with a reduced risk of DLBCL in women.
23
 Furthermore, pregnancies 
are significantly related to a decreased NHL risk.
28,29
 This could partially be explained by the 
fact that exposure to reproductive hormones such as estrogen may alter immunity and slower 
NHL development in women.
23
 With respect to post-menopausal hormone therapy, some 
studies showed that compared with non-users, estrogen therapy causes a decreased NHL risk, 
while other reports demonstrated an increased risks among long-term users compared with 
non-users.
30,31
 From the above studies, sex hormone-modulated NHL may be complex, and 
this could partially be explained variation in steroid metabolism, the presence of sex hormone 
receptors in relevant target cells and an interaction between the endocrine and immune 
systems.
29
 Given the existing complexity in the endocrine system, immune system and the 
heterogeneous features of NHL, there is an important need to uncover the association 
between sex hormones and NHL development and progression and to understand the 
underlying molecular mechanisms.    
1.6 ESTROGEN RECEPTOR SIGNALING 
1.6.1 Estrogens  
Estrogens are C18 steroid hormones derived from cholesterol. Under the cleavage by 
cytochrome P450 enzymes, different steroids are formed by reducing carbon atoms number 
from 27 to 18. The last step in the synthesis of estrogen involves aromatization of the A-ring 
of androgens (testosterone) (Figure 2), a process executed by the aromatase enzyme 
(encoded by gene CYP19A1), which is mainly expressed in the ovary and placenta, but also 
in various extra-gonadal tissues like liver, brain, adipose tissue and skin fibroblasts.
32-36
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Estrogens are present physiologically in the form of 17β-estradiol (E2), estrone (E1) and 
estriol (E3). E2 is the main physiologically active form and with higher relative binding 
affinity to the estrogen receptors.
36
 With regard to pre-menopausal women, the primary 
source of estrogen is the granulosa cells in the ovaries, and estrogen production varies 
cyclically.
37,38
 In postmenopausal women, serum estrogen concentration (< 20 pg/ml) is 
lower than in pre-menopausal women (40-500 pg/ml), and the source is from androgens 
produced in the adrenal cortex, which undergo conversion to estrogen in extragonadal tissues 
by aromatase.
37
 The primary source of estradiol in male is adipose tissue and testis, where 
testosterone is converted into estradiol in the process of aromatization.
36,39
 Estrogens play 
important roles both in physiological and pathological processes like cell growth, 
development and differentiation. The effects of estrogens are found in uterus, breast tissue, 
central nervous system, bone, immune system and many other organ systems. For instance, 
the growth of ductal epithelium and connective tissue in human breast tissue is stimulated by 
estrogens, thus being a risk factor for development of breast cancer.
37
 
 
Figure 2: Classical pathway of estrogen biosynthesis from cholesterol.
36
 
1.6.2 Estrogen receptors 
Estrogens function in their target tissue through two nuclear receptors, estrogen receptor α 
(ERα) and estrogen receptor β (ERβ), which are the products of two separate genes, ESR1 
and ESR2, respectively.
40
 The ERs belong to the nuclear receptor family and are widely 
expressed in many tissues, although ERα and ERβ show a different tissue distribution. ERα 
expression is mainly found in reproductive tissues, breast, bone, kidney and liver, while ERβ 
is mainly expressed in the central nervous system, cardiovascular system, male reproductive 
organs, lung, colon and the immune system.
40-42
 In lymphocytes, ERβ has been shown to be 
highly expressed. Furthermore, in lymphomas, ERβ expression is also very high (Figure 3) 
while ERα level is very low or undetectable.42,43 The two ERs may display their different 
functions by recruiting co-regulators (either co-activator or co-repressor) to specific genome 
targets, thus regulating different gene expression.
44
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Generally, the ER proteins like other nuclear receptors can be divided into six structural 
regions, which have different functions and are labelled from A to F (Figure 4). The A/B 
region contains a transactivation domain (AF1), which is independent of ligand binding. This 
region interacts with co-regulators contributing to tissue and gene specific responses. The C 
region contains the DNA binding domain (DBD), which is required to bind to so called 
estrogen response elements (EREs) present in the target genes. The D region contains a 
nuclear localization signal, which helps the transport of ERs into the nucleus. The E/F region 
harbors the ligand-binding domain (LBD) and a transactivator domain (AF2), where LBD is 
responsible for ligand binding and AF2 is a ligand-dependent transactivation domain. The 
AF2 region recruits co-activators or co-repressors thereby contributing to target gene 
activation or repression.
44
 The structure of the two ER subtypes is similar but not identical. 
When comparing the domains between ERα and ERβ, the DBD domain has 96% conserved 
residues, the LBD domain shows 58% conserved residues, while the conserved residues in 
the AF1 domain is only 20%.
44,45
 The difference in the AF1 domain most likely explains the 
differences in target gene activation of ERα and ERβ. The structural differences in the LBD 
domain have enabled the development of ER subtype specific ligands. When ER ligands bind 
to the LBD domain of the receptors, a protein conformational change will be introduced, and 
this is followed by chaperone protein dissociation from the ERs. After that, dimerized ERs 
translocate from the cytoplasm to the nucleus and bind to the specific EREs in the targeted 
DNA.
44
 After the binding to EREs, the ERs recruit related co-activators or co-repressors to 
form multi-protein complexes to activate or repress gene transcription respectively.
44
 In 
addition, ligand bond ERs can also interact with DNA indirectly through other transcription 
factors like AP1 and NF-κB, a mechanism called tethering.44 Apart from the classical 
pathway of ligand-dependent ER activation, ER mediated transcription in the absence of 
ligand binding has also been observed. It is reported that ER activation can be mediated by 
e.g. epidermal growth factor receptor and insulin-like growth factor 1 receptor in the absence 
of its ligands by phosphorylation.
46
 
Both of the two ER subtypes exist in different isoforms derived from alternative splicing 
(Figure 4). These splice variants are different from the wild type receptors in structure and 
function, and they are present in both normal and malignant tissues. For example, ERα-36 is a 
truncated form of wild type ERα. It has been reported to confer endocrine resistance in breast 
cancer in the presence of wild type ERα. In the case of ER, five splice variants have been 
described (ER1-5, ER1 being the wild type ER). To note is that only the wild type ER1 
binds ligands efficiently. An important ERβ splice variant is ERβ2 (also called ERcx), 
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which in some tissues/cells have been described to be expressed at even higher levels than the 
wild type ER1. The physiological role of ER2 is not well established but it has been 
suggested that it modulates the transcriptional activity of wild-type ERβ (ERβ1) and 
antagonize wild type ERα through heterodimerization.  Moreover, wild type ERα and ERβ 
form homodimers and may even form a heterodimer. In contrast, ERβ2 and ERβ5 can only 
form heterodimer with wild type ERs resulting in inhibition of receptor binding to ERE.
44,47
   
 
Figure 3: ESR2 is highly expressed in lymphatic malignancies. The data is generated from 
Cancer Cell Line Encyclopedia database (https://portals.broadinstitute.org/ccle/home).  
 
 
Figure 4: Structural and functional domains of the ERs and splice variants.
44
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1.6.3 Different functions of ERα and ERβ, respectively 
Although ERα and ERβ share similar activation mechanism, they usually have different roles 
in regulating cell proliferation and apoptosis.
48
 For example, ERα signaling has been shown 
to promote cell proliferation while ERβ seems to inhibit proliferation.49 Similarly, it has been 
reported that ERα positively regulates nuclear transcription factor MYC, while ERβ does the 
opposite.
50
 Interestingly, when ERβ was introduced into ERα positive breast cancer cells in 
vitro, repression of cell proliferation was observed.
44
 The different responses to ER and 
ER, is likely explained by differences in the protein structures, particularly of AF1 domain, 
which is involved in recruitment of co-regulator proteins. ERα and ERβ share only 20% 
amino acid similarity in their AF1 domain.
44
 
1.6.4 Estrogen receptor β activation and tumor inhibition 
Although there is a controversy about the normal role of ER in vivo as derived from Esr2-
knockout mice generated in different labs, an ERβ tumor suppressive function is more 
commonly accepted considering its clear anti-proliferative effect in in vitro and in vivo cancer 
models. For example, in the prostate epithelium of Esr2-knockout mice, epithelial hyperplasia 
has been observed. In line with the above results, prostate cancer cell proliferation, migration 
and invasion is inhibited by ERβ overexpression.51,52 Furthermore, DNA methylation of the 
ERβ promoter region, thereby reduced expression, is found in more aggressive prostate 
tumors.
53
 Moreover, in squamous cell carcinoma mouse model, ERβ overexpression or ERβ 
agonist treatment increased the expression of NOTCH1, inhibiting the growth of tumor and 
promoted tumor differentiation both in vitro and in vivo.
54
 Furthermore, ERβ selective agonist 
KB9520 not only showed an anti-proliferative effect on malignant pleural mesothelioma 
cells, but also sensitized the cells to cisplatin induced pro-apoptotic effect.
55
 
Although ERβ seems to inhibit tumor growth of several cancer forms, its mechanism of 
action is still not clear. ERβ has been reported to inhibit tumor growth in G1 phase by 
regulating cell cycle checkpoint related factors like CCND1, p21, MYC, FOXO1 and 
p53.
56,57
 Recently, ERβ was found to reduce cell survival by regulating RAS signaling 
pathway in Non-small cell lung cancer.
58
 In prostate cancer cells, researchers also found that 
ERβ could decrease phosphorylation of AKT (Th308), increase the expression of FOXO3a 
and PUMA which was followed by apoptosis triggered in a ligand (5α-androstane-3β,17β-
diol) dependent way.
59
 This suggests that activation of ERβ by ERβ agonist could be a novel 
strategy to kill prostate cancer cells. In line with the above observation of ERβ anti-
proliferative effects in cancer cells, we have found in our experiments that activation of ERβ 
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by its selective agonists DPN or KB9520 can repress murine lymphoma growth in vivo which 
involves both inhibition of proliferation and increased apoptosis.
42
  
1.7 B CELL RECEPTOR (BCR) SIGNALING IN B CELL LYMPHOMAS 
1.7.1 BCR signaling 
BCR signaling is essential for the proliferation of both normal B cells and B cell 
malignancies (Figure 5). This involves increased levels of phosphorylated (active) Bruton 
tyrosine kinase (BTK) and SYK, two downstream signaling components of the BCR 
pathway,
60-63
 which in turn results in high nuclear factor-kB (NF-κB) activity through the 
canonical NF-κB signaling pathway. Increased NF-κB signaling has been shown to play a 
central role in e.g. the pathogenesis of MCL and ABC-DLBCL. In addition, BCR signaling 
induces activation of Phosphoinositide-3 kinases (PI3K)/AKT, RAS, MAPK and nuclear 
factor of activated T cell pathway (NF-AT), which all contribute to cell survival, 
proliferation, adhesion and migration.
64,65
 
 
Figure 5: B cell receptor signaling.
60
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1.7.2 NF-κB signaling 
NF-κB signaling is a very well-studied pathway in normal and cancer cells. The NF-κB 
proteins are critical regulators of important physiological processes like immunity, 
inflammation, proliferation and apoptosis. They have also been suggested to play a survival 
role in many forms of tumors due to constitutive activation. Constitutive NF-κB signaling 
also plays an important role in human B-cell malignancies. NF-κB activation occurs 
downstream of numerous receptors like the BCR, CD40, Toll like receptor 4 and B cell 
activating factor (BAFF) receptor.
66
 NF-κB signaling can be subdivided into a classical 
pathway and an alternative pathway, which have different roles in cell physiology and 
pathology. In the classical NF-κB pathway, receptor activation leads to phosphorylation of 
the IκB kinase β (IKKβ) subunit in the IKK complex (three subunits: IKKα, IKKβ and 
NEMO/IKKγ), where after IKKβ phosphorylates IκBα, the inhibitor of NF-κB dimerization 
(p50/p65 and p50/c-Rel). Phosphorylation of IκBα leads to a proteasome-mediated 
degradation of IκBα allowing NF-κB dimers to translocate to the nucleus, bind to DNA and 
activate transcription of target genes.
66
 In the cases when the alternative NF-κB pathway is 
activated, the IKKα subunit is phosphorylated by the kinase NIK. IKKα phosphorylates p100, 
leading to its cleavage into the p52 subunit, which pairs with another subunit, RelB, where 
after the p52/RelB dimer translocates to the nucleus.
67
 Both of these two NF-κB signaling 
pathways play important roles in the survival and proliferation of normal B-cell development 
and B-cell malignancies.  
With respect to MCLs pathology, it has been reported that in both MCL patient samples and 
MCL cell lines, NF-κB is constitutively activated and plays an important role in regulating 
MCLs survival and growth. In B cells, the classical NF-κB pathway is activated by protein 
kinase Cβ, which is the target of diacylglycerol, released upon BTK activation. By activating 
the classical NF-κB pathway, BTK plays an essential role in BCR signaling of normal B cell 
proliferation as well as in B cell malignancies including MCL.
68,69
 Interestingly, researchers 
have found that some MCL lines rely on chronic BCR classical NF-κB signaling and are 
highly sensitive to the PKC inhibitor sotrastaurin, while other MCL cell lines which are 
dependent on the alternative NF-κB pathway for survival, are resistant to this drug.70 The 
above finding suggests that different B-cell lymphoma subtypes may rely on classical and 
alternative NF-κB signaling pathways, respectively. 
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1.7.3 PI3K/AKT signaling 
PI3K belongs to the family of lipid kinases translating extracellular signals into intracellular 
signals that regulate many physiological functions and cellular processes.
71-73
 Aberrant PI3K 
activation is seen in cancers, and it is considered to be part of the MCL pathogenesis.
74
 PI3K 
activates its downstream target serine-threonine kinase AKT, which plays an important role 
in promoting MCL survival and progression by stabilizing CCND1 mRNA and by preventing 
CCND1 nuclear export.
75,76
 The family of PI3K consists of four families (class I, II, III, and 
IV), in which class I PI3K is most well studied.
77
 Class IA PI3K transduces signals from 
receptors tyrosine kinases leading to cell survival and growth.
71
 The PI3K class IA consists of 
one of three catalytic subunit isoforms, p110α (encoded by PIK3CA), p110β (encoded by 
PIK3CB), and p110δ (encoded by PIK3CD) which dimerizes with p85 regulatory subunit.76,78 
It has been reported that p110δ is highly expressed in MCL, contributing to BCR-induced 
PI3K activation, while p110α expression level in MCL varies greatly, playing a role in 
maintaining constitutive PI3K activation.
76
 Moreover, some observations have demonstrated 
that PIK3CA gene amplification contributes to the MCL pathogenesis and those MCL 
patients who relapse express more p110α compared with chemotherapy sensitive patients.76,79  
1.8 THE TUMOR MICROENVIRONMENT (TME) IN B CELL MALIGNANCIES 
TME with its non-malignant cells (e.g macrophages and T cells) and stromal components has 
a major influence on tumor cells when it comes to tumor proliferation, survival, 
dissemination and resistance to therapy. This is also the case for NHL.
80
 Evidence for TME 
involvement in lymphoma development includes experiments demonstrating a correlation 
between the presence of e.g. macrophages or T cells with clinical outcome.
81-83
 Furthermore, 
recent results suggest the interaction between the TME and lymphoma cells to be 
bidirectional with the lymphoma cells secreting cytokines which in turn attract non-malignant 
cells like macrophages, immune- and stroma cells that influence the tumor cells.
80
 Extrinsic 
stimulation by the TME through the BCR plays a central role in proliferation and survival of 
normal and malignant B cells.
84
 This highlights the importance of the TME in B cell 
lymphomas. 
Lymphomas can derive from developing lymphocytes at different developmental stages. For 
B-cell lymphomas, their development usually happens in lymphoid structures in which 
normal T-cell, other cells or stroma may interact with the tumor cells, stimulating lymphoma 
cell survival.
85
 The B-cell lymphoma TME contains stromal cells, blood vessels, immune 
cells and extracellular matrix. When normal lymphoid tissue is infiltrated by lymphoma cells, 
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a mutual interaction between the lymphoma cells and the microenvironment occurs which 
support lymphoma cell survival or dissemination.
80
  
Both direct cell-to-cell contacts and soluble factors of the TME may contribute to the survival 
signal. The MCL adhesion molecule very late antigen-4 (VLA-4) has been shown to interact 
with extracellular matrix proteins such as fibronectin or vascular cell adhesion molecule 1 
expressed on stromal cells, followed by triggering of survival signals.
86
 In addition, soluble 
factors secreted by the TME also promote tumor cell survival and proliferation. Paracrine 
interleukin-6 (IL6) can prevent MCL from spontaneous apoptosis and blocking the IL6 
receptor gp80 or neutralizing IL6 can inhibit cell growth and induce cell apoptosis. Moreover, 
IL6 has been shown to activate the Jak2/STAT3 and PI3K/Akt pathways in MCL.
87
 Another 
study showed that IL4 secreted by T Follicular Helper cell can stimulate progression of FL by 
activating the STAT6 signaling pathway in a paracrine manner.
88
 Furthermore, stromal cells 
may also secrete soluble factors like BAFF to protect e.g. DLBCL and MCL from 
apoptosis.
89
  
1.9 LYMPHOMA MICROENVIRONMENT AND DRUG RESISTANCE 
Beyond the experimental evidence for a role of the TME for lymphoma growth, survival and 
dissemination, there are more and more clinical or pre-clinical evidence demonstrating that 
the interaction between lymphoma tumor cells and its microenvironment plays an important 
role in altering the sensitivity of the lymphoma cells to chemotherapy.
80
 For example, bone 
marrow stromal cells have been shown to protect NHL cells from mitoxantrone treatment-
induced cell apoptosis, which occurs through NF-κB-mediated upregulation of anti-apoptotic 
proteins.
90
 Lymphoma cell adhesion to follicular dendritic cells (FDCs) mediates cytotoxic 
drug resistance due to the induction of miR-181a and a reduced level of the pro-apoptotic 
protein BIM.
91
 Furthermore, direct FDC and lymphoma interaction has been shown to 
increase the activity of MYC by down-regulating miR-548m expression level and to enhance 
HDAC6 expression leading to lymphoma survival following treatment by cytotoxic drugs.
92
 
Some studies partially explain the drug resistance mechanism by stating that lymphoma cell 
adhesion to stromal cells causes cell cycle arrest, which will prevent the cytotoxic effects of 
chemotherapy.
93
  
It is known that MCL as a kind of incurable NHL with high relapse rate and poor prognosis, 
in advanced stages often home to the bone marrow compartment, from where the cells will 
obtain survival signals, making the tumor cells more prone to resist drug-induced effects.
50
 It 
has also been shown that mesenchymal stromal cells protect MCL cells from doxorubicin, 
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fludarabine or bortezomib-induced apoptosis by inducing secretion of BAFF and activation 
of canonical and alternative NF-κB signaling.94 IL6 has been reported to derive from cells of 
the TME or the MCL cells themselves and plays a central role in MCL cell survival and drug 
(bortezomide) resistance.
87
 Taken together, this shows that the TME-MCL interaction 
contributes to drug resistance in vivo, which in turn underlies the cause for minimal residual 
disease and relapse. 
1.10 IBRUTINIB TREATMENT AND RESISTANCE IN MCL 
1.10.1 Ibrutinib effect on MCL 
Targeting BCR signaling using BTK inhibitors has been shown as a promising therapeutic 
strategy in clinical studies of some lymphomas. In a recent Phase II trial of MCL, the BTK 
inhibitor ibrutinib showed an encouraging effect. In MCLs patient, an overall response rate of 
68% was observed, 21% of MCL patients achieved a complete response while 47% achieved 
a partial response. Based on these promising results as well as limited side effects by 
ibrutinib, the U.S. Food and Drug Administration (FDA) did approve ibrutinib in 2013 for the 
treatment of MCL patients who have received and failed at least one prior therapy, and in 
2014, FDA has also approved ibrutinib for treating CLL patients and later for Waldenström's 
macroglobulinemia. Trials for treatment of additional lymphomas with ibrutinib, is ongoing. 
1.10.2 Ibrutinib resistance in MCL 
A follow-up clinical study by Wang and coworkers,
95
 in which the BTK inhibitor ibrutinib 
was evaluated, showed an overall response rate in 67% (complete response in 23%) of 111 
MCL cases which previously had shown primary or developed resistance to treatment by 
other drugs. The remaining one-third of the MCL patients was refractory to ibrutinib 
treatment. In a study by another group involving 114 MCL subjects with therapy resistance to 
other drugs, a complete or partial ibrutinib response rate of 50% was seen.
96
 Primary 
resistance to ibrutinib in non-responsive MCL has been explained by constitutive activation 
of the alternative NF-κB signaling pathway not targeted by BCR signaling inhibitors like 
ibrutinib, which only hampers the canonical NF-κB signaling pathway.70 In this study, it was 
reported that 16% of the MCL patients had a deregulated alternative NF-κB signaling 
pathway as a result of inactivating mutations in TRAF2 or BIRC3, two genes that are 
involved in suppressing the alternative NF-κB signaling.70 Moreover, next-generation 
sequencing has revealed additional somatic mutations that may contribute to primary drug 
resistance by BCR signaling inhibitors e.g. NOTCH1 or CARD11.
97-99
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In addition to primary resistance, acquired (secondary) resistance may develop, which is not 
an uncommon phenomenon in cancer treatment, also with modern targeted drugs. Although 
the initial response of MCL to treatment often is positive, still most patients eventually 
relapse. Though 50-67% of MCL patients treated with ibrutinib showed a complete or partial 
response upon start of ibrutinib treatment (see above), the median duration of response was 
limited to 3.5-17.5 months, where after drug resistance developed.
95,96
 In some, but in a very 
limited number of the cases, could the ibrutinib resistance in relapsing MCL patients be 
attributed to an acquired mutation in the BTK (C481S) not present before the start of the 
ibrutinib treatment.
100,101
 The C→S mutation of amino acid residue 481 in the active site of 
BTK disrupts binding of ibrutinib to BTK, explaining the acquired resistance to ibrutinib. 
Acquired resistance to ibrutinib still develops in patients with non-mutated BTK post-
ibrutinib treatment relatively rapidly. As demonstrated by Martin et al,
96
 only 1 out 8 patients 
with non-mutated BTK post ibrutinib treatment experienced durable response >1 year. 
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2 AIMS OF THE STUDY  
For most subtypes of lymphomas, the risk of developing these malignancies is higher in 
males compared to females. Furthermore, prognosis is usually poorer in males vs. females. 
Additionally, epidemiological data have suggested that sex hormones, particularly estrogens, 
may play a role in this gender difference in lymphoma development. Despite this, lymphomas 
are not considered as sex hormone-regulated malignancies and the molecular mechanisms for 
this hormone regulation is lacking.  Based on this and some previous studies in the group on a 
murine lymphoma, the investigation of this thesis aimed to answer the following questions: 
1. What roles do estrogens and androgens have in regulating lymphoma progression? 
2. What are the mechanisms for sex hormone effects on lymphoma progression and 
which receptors are involved? 
3. Can selective estrogen receptor agonists be used to diminish lymphoma progression? 
4. How does ER expression look like in clinical lymphoma samples and can ERact 
as a prognostic marker? 
MCL is known to be an aggressive NHL with poor prognosis, although initial treatment 
results often are positive, development of treatment resistance and relapse most often occurs, 
also following treatment with more modern targeted drugs like ibrutinib. Thus, there is a 
great need for alternative approaches in the treatment of aggressive NHL. In order to uncover 
the mechanism and overcome ibrutinib resistance, we focused on the TME, as the TME has 
been shown to protect tumor cells from cytotoxic effects induced by conventional 
chemotherapies. Thus, except analyzing if MCL progression can be impaired by treatment 
with selective ER agonists (see above), we also wanted to investigate if sensitivity of MCL 
to ibrutinib could be potentiated 
     5. By analyzing the impact and mechanisms of stromal cells on the sensitivity of MCL 
cells to ibrutinib and to identify ways to overcome stromal cell-mediated ibrutinib resistance.  
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3 RESULTS AND DISCUSSION  
3.1 ESTROGEN EFFECTS ON LYMPHOMA PROGRESSION (PAPER I-III) 
3.1.1 Systemic estrogens play a protective role in lymphoma progression 
(Paper I and Paper II) 
Epidemiological studies have demonstrated a higher incidence and poorer prognosis of 
most lymphoma subtypes in males compared to females. Furthermore, epidemiological data 
have shown that lymphoma development may be under the control of sex hormones, 
particularly estrogens. Despite this, lymphomas are not considered as hormone-related 
malignancies. Previous studies in the group had shown that an allografted murine T cell 
lymphoma grew faster in male mice as compared to female mice, a difference that was 
abolished following ovariectomy.
42
  This suggested a role for estrogens in the control of 
progression of this lymphoma. To investigate if there was a gender difference of tumor 
growth also for human lymphomas, human DLBCL cells were grafted to 
immunocompromised NSG mice. As can be seen in Paper I Fig.1, tumors derived from the 
human ABC-DLBCL lymphoma grew slower in female vs. male mice, demonstrating that 
there is a gender difference in tumor growth both for murine and human, as well as for B 
and T cell tumors.  Further support for this was gained by investigating the role of male sex 
hormones in the development of lymphomas. After castration, male mice were grafted with 
the murine T-cell lymphoma EG7 and we found that the castrated mice showed faster 
lymphoma growth compared to sham-operated mice. However, since androgens can be 
converted to estrogens by the enzyme aromatase (expressed by the CYP19A1 gene), we 
wanted to distinguish whether the effect was a direct androgen effect (via the androgen 
receptor (AR)) or occurred indirectly by androgen conversion to estrogens. This was done 
by administrating the aromatase inhibitor (AI) Letrozole, which prevents androgen to 
estrogen conversion or the AR antagonist Bicalutamide to intact male mice which had been 
grafted with EG7 lymphoma cells. We observed that Letrozole administration resulted in a 
faster tumor growth while Bicalutamide treatment did not show any effect on tumor growth 
compared to vehicle treated mice. These results showed that the effect was not mediated by 
a direct androgen (via AR) effect but rather an indirect effect via ER by inhibiting androgen 
conversion to estrogens. This conclusion was supported by the lack of effect on lymphoma 
growth by dihydrotestosterone (DHT), a potent AR agonist but which can’t undergo 
aromatization to an estrogen. The same stimulation of lymphoma growth by various AI’s 
was seen when analyzing human Granta-519 MCL xenografts in immunocompromised 
NGS mice. These results showed that the lymphoma growth promoting effect also occurs 
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with human lymphomas and that both T and B cell lymphomas are affected. Since the AI’s 
enhanced lymphoma growth in immunodeficient mice, it also showed that the effect is 
independent of an intact adaptive immune system (Paper II). The above results highlight 
the important role of estrogens in protecting against lymphoma progression and raise 
concern whether women with breast cancer treated with AI may have an increased risk for 
lymphoma development (at least progression if lymphoma initiation has occurred). Taking 
the above experimental data from our group together with the epidemiological data strongly 
support that lymphoma development, particularly progression, is under sex hormone 
control. Thus, lymphomas should be considered as hormone-regulated cancers. 
3.1.2 ERβ activation by its agonists inhibit lymphoma growth (Paper I and 
Paper III) 
We have previously shown that murine T-cell lymphoma (EG7) cells express ER (but 
very little or no ER) and that EG7 lymphoma growth can be repressed following ERβ 
activation in an allograft mouse model.
42
 Whether this repression of tumor growth in vivo 
was a direct effect on the tumor cells or also involved indirect effects via ER activation of 
cells of the TME or other tissues was not determined. To study this, we treated ERβ-
deficient (BERKO) mice and wild-type mice grafted with ERβ positive EG7 lymphoma 
cells with the ERβ selective agonist DPN and found that DPN inhibited ERβ positive EG7 
lymphoma tumor growth similarly in both wild-type and ERβ-deficient mice. This result 
suggests that ER agonists exert a direct effect on the EG7 cells and not indirectly through 
the TME or other tissues. However, caution with such a conclusion should be taken, since it 
has been demonstrated that the BERKO ER-deficient mice may express truncated versions 
of ER which still may exert some effects.  
The ability of selective ER agonists to suppress tumor growth was also seen in mice 
grafted with human B-cell lymphomas e.g. Granta-519 MCL cells and DLBCL cells, which 
express ERβ mRNA and protein, while ERα levels are very low, (Paper I, Fig. 2; Paper 
III, Fig. 2). In the latter case, impaired tumor growth by the ERβ selective agonist DPN 
was seen both in mice grafted with GCB-DLBCL (SU.DHL4) and ABC-DLBCL (U2932)  
cells demonstrating that inhibition of DLBCL growth by ERβ is independent of whether 
NF-κB activity is high (U2932 ABC-DLBCL) or low (SU.DHL4 GC-DLBCL) (Paper I, 
Fig. 3). Impaired lymphoma growth following ER agonist treatment was also seen in 
tumors derived from Raji BL cells (Paper III). The ability of selective ER agonists, 
particularly KB9520 which has a 700-fold selectivity for ER activation over ER 
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activation (Paper III) to suppress tumor growth, supports that the main contributor to the 
tumor inhibiting effect is ERβ. Importantly, the ERα selective agonist PPT had no effect on 
tumor growth, excluding the possibility of an ERα-mediated effect. The ER antagonist 
ICI182.780 could partially block the tumor suppressing effect of DPN, further supporting 
engagement of ER signaling in the response. Interestingly however, ICI182.780 seems by 
itself to act as a partial agonist on the ER as defined by its ability by itself to partially 
block tumor growth (Paper III).  Another interesting observation was that E2, which binds 
to ER with the same affinity as it binds to ER, did not repress MCL tumor growth 
(Paper III) and to a very limited extend repressed EG7 lymphoma growth
42
.  The cause for 
E2’s inability to repress lymphoma growth despite its ability to activate ER (at least is 
other cells) is unclear, but may be explained by an inability of the E2-ER complex to 
recruit proper co-regulators in the lymphoma cells.  
The target genes of ER in repressing lymphoma growth are still unclear. However, we 
identified two genes in the Granta-519 MCL tumors that could participate in this process, 
namely the tumor proliferation gene GRB7 and the B cell survival gene, BAFF. Expression 
of the genes were down-regulated by the DPN treatment. (Paper III, Figs. 2, S3 and S4). 
Collectively, ERβ activation inhibits the growth of a number of NHLs with different origins 
and molecular characteristics. This suggests that the mechanisms for the tumor repressing 
effect by ER in various lymphomas should be more general and uncovering this 
mechanism would be both theoretically important (explain the gender difference in 
prognosis and possibly incidence) and clinically significant as a new treatment option.  
3.1.3 Lymphoma vascularization and dissemination are inhibited by ERβ 
agonist treatment (Paper III) 
By analyzing tumor material derived from Granta-519 MCL cell engrafted mice, we 
observed downregulated expression of different vascularization related genes following 
DPN treatment. This included down-regulated mRNA expression of LYVE-1 (a marker of 
lymphoendothelial cells), CD34 (partially a marker for blood vessels) and angiogenin. The 
down-regulated LYVE-1 mRNA expression was associated to a reduced number and size 
of lymph vessels as determined by immunohistochemistry. The reduced vascularization 
correlated to a down-regulation of vascular endothelial growth factor C mRNA expression, 
supporting that ERβ activation inhibits tumor lymphangiogenesis and angiogenesis. 
Because tumor vascularization is considered as an important factor for tumor progression, 
including tumor growth and tumor dissemination, we also examined the effect of ERβ 
agonist treatment on lymphoma dissemination by administrating DPN to mice engrafted 
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with Raji BL cells, which previously have been reported to display significant liver 
dissemination. It was observed that ERβ activation reduced the dissemination of Raji BL 
tumors in the xenograft mouse model as indicated by both a decreased number as well as a 
reduced size of the metastatic tumors. (Paper III, Figs. 3-5; Figs. S6-8) 
3.1.4 ERβ expression in primary lymphoma samples and its potential role as 
a prognostic biomarker (Paper I and Paper III) 
To identify if ERβ is expressed also in primary lymphoma samples and not only in 
lymphoma cell lines, we identified ER1 expression in both primary MCL (Paper III) and 
DLBCL (Paper I) samples, suggesting that ERβ can be considered as a novel therapeutic 
target. We focused on ER1 expression since this is the wild-type ER variant able to 
efficiently bind a ligand (see Background). In the case of DLBCL, ER1 expression was 
found in 89% of the DLBCL samples, although at various levels. After comparing nucleus 
ERβ1 protein expression levels to clinical data, we have found a significant correlation 
between negative/low ERβ1 levels and extra-nodal localization, which may reflect that 
disseminated lymphoma cells represent a dedifferentiated cancer stage that may be 
insensitive to estrogen regulation (Paper I). No correlation to gender, DLBCL subtype (GC 
vs. non GC-DLBCL), pre- vs. postmenopausal age or other clinical characteristics was 
observed. When analyzing the correlation between ERβ1 expression levels with patient 
survival, we found that in the CHOP-treated patient cohort, intermediate/high nuclear ERβ1 
expression correlated to a favorable prognosis of both overall survival and progression-free 
survival. This is in line with observations in some other tumors.
102
 However, in the 
Rituximab-CHOP-treated patient cohort, the inverse correlation was observed with low 
ER1 expression correlating to better progression-free survival. The reason for this inverse 
relationship between ER1 expression and survival in the patient cohorts treated with 
CHOP with or without Rituximab is not clear. However, it is not due to unequal 
distribution of base line characteristics since they did not differ significantly between 
patients with high or low ERβ1 expression level. Furthermore, statistical significance was 
maintained when compared with other prognostic factors in the multivariate analysis. To 
note is that a similar phenomenon has been shown for other lymphomas where the 
prognostic impact of a biomarker is impaired or inversed after adding Rituximab to a drug 
treatment scheme.
103-105
  Independent of this, the results suggest that targeting ER1 by its 
agonists is a promising therapeutic way for treating DLBCL, and that ER1 expression can 
be used as a prognostic marker.  
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3.2 STROMAL CELL EFFECTS ON IBRUTINIB SENSITIVITY OF MCL (PAPER 
IV) 
3.2.1 Stromal cell-mediated ibrutinib resistance through regulation of AKT 
activity in MCL 
Ibrutinib administration to mice grafted with Mino MCL cells showed only a transient 
inhibitory effect on tumor growth, as with time a resistance to ibrutinib developed. In order 
to investigate whether this may be due to an impact of stromal cells on the sensitivity of 
MCL to ibrutinib, MCL cells were co-cultured with murine MS-5 stromal cells and treated 
with ibrutinib. Co-culturing the MCL cells with MS-5 stromal cells resulted in reduced 
inhibition of MCL cell proliferation by ibrutinib compared to when MCL cells were grown 
alone. Stromal cells also reduced sensitivity of Mino and Rec-1 (another MCL cell line) 
cells to ibrutinib-induced apoptosis. The above results demonstrate that stromal cells impair 
MCL cell sensitivity to ibrutinib. Importantly, if Mino cells which had become resistant to 
ibrutinib-induced cell apoptosis in the presence of stromal cells were transferred into new 
wells without stromal cells and retreated with ibrutinib, they regained sensitivity to 
ibrutinib-induced apoptosis. This confirmed that stromal cells, and not a tumor cell 
autonomous mechanism, conferred the resistance. Furthermore, the inability of stromal cell 
conditioned media to prevent ibrutinib-induced cell apoptosis demonstrated that a direct 
stromal cell-MCL interaction is the main trigger for the resistance. These results emphasize 
that apart from acquired BTK mutation for development of ibrutinib resistance, stromal 
cells have an important role in providing a protective niche to make MCL cells resist 
ibrutinib-induced effects. 
We then investigated whether the stromal cells will affect the restart of proliferation when 
ibrutinib is removed. Rec-1 MCL cells co-cultured with MS-5 stromal cells were treated 
with ibrutinib for 10 days. After 10 days of ibrutinib treatment, proliferation of Rec-1 cells 
was largely absent. However, 6 days after the ibrutinib was removed, a substantial recovery 
of proliferating Rec-1 cells was observed. When no stromal cells were present during a 2 
day ibrutinib treatment, no recurrence of proliferating Rec-1 cells was seen 6 days after 
ibrutinib was removed.  To further support that the stromal cells impaired sensitivity to the 
anti-proliferative effect of ibrutinib, the response of Rec-1 cells adhering to the stromal 
cells and the cells growing in suspension (non-adhering) were analyzed separately. The 
reappearance of proliferating cells after ibrutinib removal was shown to originate from the 
stromal adherent lymphoma cells and not from the lymphoma cells growing in suspension 
(non-adherent cells). This further supports that it is the stromal cells that confer ibrutinib 
resistance to the MCL, allowing tumor cells to regrow after ibrutinib is removed. This also 
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supports that a direct physical contact between stromal cells and lymphoma cells is required 
to confer the ibrutinib resistance.  
Ibrutinib regulates both the BCR-NF-B and PI3K/AKT signaling pathways. Our initial 
results indicated that the inhibitory effect of ibrutinib on the NF-kB signaling pathway in 
MCL cells remained intact in the presence of MS-5 stromal cells. We therefore focused our 
investigation on the effect of stromal cells on the PI3K/AKT signaling pathway. In the 
absence of stromal cells, ibrutinib strongly reduced pAKT (Ser473) levels, while co-
culturing the lymphoma cells with MS-5 stromal cells impaired the ibrutinib-mediated 
down-regulation of pAKT. In the cases when Mino, Rec-1 and Jeko-1 cells were co-
cultured with human FDCs, increased levels of pAKT was seen. These results suggest that 
stromal cell interaction with MCL cells increase pAKT levels or impair ibrutinib-mediated 
down-regulation of AKT signaling in the MCL cells. 
3.2.2 Overcoming stromal cell-mediated ibrutinib resistance 
In order to test if the increased pAKT activity in MCL cells conferred the stromal cell-
mediated ibrutinib resistance, we screened inhibitors of PI3Ks for their ability to restore 
MCL cell sensitivity to ibrutinib-induced apoptosis in the presence of MS-5 stromal cells. 
Mino cells were treated with different PI3K inhibitors alone or in combination with 
ibrutinib. Combined treatment between ibrutinib and BYL719, a PI3K inhibitor, resulted 
in a strong apoptotic response with a clear synergistic effect compared with single drug 
treatment. The pro-apoptotic effect of ibrutinib+BYL719 was much more pronounced than 
the effect seen when ibrutinib was combined with other drugs, including inhibitors of other 
PI3K family members. Treatment with either ibrutinib or BYL719 resulted in reduced 
levels of pAKT in the lymphoma cells. Combined treatment with ibrutinib and BYL719 
resulted in at least an additive inhibitory effect on pAKT levels. Importantly, a synergistic 
effect of BYL719 and ibrutinib on the induction of apoptosis in the presence of stromal 
cells was also seen in primary MCL cells. The above results further confirm that AKT 
activity confers ibrutinib resistance. We also observed that ibrutinib and BYL719 inhibited 
cell proliferation separately, and no additive effect was seen when combined. However, in 
the case when MCL (Mino)-stromal cells (MS-5) co-cultures were initially treated with 
ibrutinib before it was removed, restart of Mino cell proliferation in the presence of MS-5 
stromal cells occurred. In contrast, impaired restart of Mino cell proliferation was seen in 
culture plates that were treated initially with both ibrutinib and BYL719 before drug 
removal. This correlated to a down-regulation of pAKT levels as demonstrated in the Mino 
cells. This suggests that PI3Kα inhibition also can overcome the anti-proliferative 
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resistance to ibrutinib conferred by the MS-5 stromal cells. Although ibrutinib only showed 
a transient effect on MCL tumor growth in vivo (see above), a significant and synergistic 
inhibition of tumor growth in vivo was observed when ibrutinib and BYL719 were 
administrated together. Collectively, these results show that addition of a PI3Kα inhibitor to 
ibrutinib can overcome (or delay development of) ibrutinib resistance in MCL. 
As cell adhesion to stromal cells is required for the development of MCL cell resistance to 
ibrutinib, we investigated whether adhesion molecules expressed on MCL’s and stromal 
cells may play a role in the development of ibrutinib resistance. Based on published data, 
the adhesion molecule VLA-4 is highly expressed on several MCL cell lines (the Cancer 
Cell Line Encyclopedia (CCLE, https://portals.broadinstitute.org/ccle/home). To 
demonstrate whether VLA-4 was involved in the development of ibrutinib resistance, Mino 
and MS-5 cell co-cultures were treated with a VLA-4 (CD49d) blocking antibody. We 
observed that the VLA-4 blocking antibody strongly reduced Mino cell adhesion to the 
stromal cells, suggesting that the VLA-4 indeed is involved in the attachment. Furthermore, 
combined treatment with ibrutinib and VLA-4 blocking antibody not only impaired the 
restart of MCL cell growth after drug removal, but also synergistically induced cell 
apoptosis compared to single drug treatment. Moreover, treatment with ibrutinib+VLA-4 
blocking antibody further reduced pAKT levels when compared to ibrutinib±IgG treatment 
These results clearly demonstrate that stromal cell interaction with VLA-4 plays an 
important role in evoking the stromal cell-mediated ibrutinib resistance. 
The above results clearly demonstrated that stromal cells should be considered to be an 
important contributor to ibrutinib resistance. They not only provide the tumor cells with a 
protective niche to avoid cell apoptosis, but also support tumor cell regrowth after cessation 
of ibrutinib treatment. Importantly, the results suggest ways to overcome stromal cell-
mediated ibrutinib resistance by inhibiting either PI3K or blocking VLA-4 signaling. 
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4 CONCLUSIONS, SIGNIFICANCE AND FUTURE 
PERSPECTIVES  
4.1 THE MECHANISMS OF ERΒ-MEDIATED NHL INHIBITION AND 
TRANSLATIONAL ASPECTS 
We experimentally demonstrate that estrogens play a protective role in lymphoma 
progression. We also show that ERβ selective agonists inhibit lymphoma growth. 
Interestingly, this seems to be the case for all the lymphoma subtypes so far tested (MCL, 
DLBCL and BL). ERβ selective agonists not only inhibit lymphoma growth, but also impair 
tumor dissemination, which in MCL, at least partly, can be explained by inhibition of tumor 
vascularization. Considering the potent inhibition of lymphoma growth by ERβ agonists (at 
least as good as the newly developed targeted drug ibrutinib, data not shown), the ER seems 
to be a useful target for development of new drugs against lymphomas. The use of highly 
ER selective agonists (alone or in combination with other targeted drugs operating through 
other signaling pathways) should reduce side effects normally linked to the use of non-
selective estrogens also interacting with ER. Selective ER agonists that have been used in 
clinical trials to treat other diseases have shown that they are safe.  
Interestingly, a majority of the lymphomas seems to express ER1 (>89% of primary 
DLBCL samples, 4 out of 4 tested primary MCL samples), the ER isoform capable of 
binding a ligand. Furthermore, identifying ER1 expression in individual lymphoma samples 
should be valuable    in recognizing patients that may benefit from selective ER1 agonist 
treatment, similar to the situation for breast cancer where ER expression will determine if 
the patient will undergo treatment with ER antagonists or aromatase inhibitors. In addition 
establishing ER1 expression in the lymphoma samples may also be a useful biomarker for 
evaluating prognosis. To note is that this study does not consider a function for the non-
ligand-binding ER2-5 isoforms for responsiveness or as a prognostic indicator. In fact, some 
studies of other cancer forms have shown that for example ER2 and ER5 may equally or 
better correlate to prognostic outcome.
106-108
 In the case of CLL, it has been shown that high 
nuclear ER2 expression is a poor prognostic factor.109 Thus, further investigations about the 
roles of the ER splice variants in lymphomas are necessary. 
Although several experiments suggest that the growth inhibitory effect of the selective ERβ 
agonists are mediated via ERβ (high selectivity of DPN and especially KB9520 for ER 
binding; the ER antagonist ICI182.780 blocks the effect of selective ERβ agonists DPN; 
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selective ERα agonist PPT does not cause inhibition of tumor growth), definitive proof of an 
ERβ-mediated effect is still lacking. In order to finally establish an ERβ-mediated effect, a 
lymphoma cell in which ER expression has been ablated or knocked down is needed. Our 
attempts to establish such a lymphoma cell line have so far failed. Such ER lymphoma cell 
line would be useful to test in xenograft tumor mouse models where the effect of ERβ 
selective agonists can be compared to the response of tumors generated by control lymphoma 
cells in which ERβ expression has not been altered. 
An additional puzzling observation which so far has not obtained a clear explanation is the 
clear increase in lymphoma tumor growth following ovariectomy or blocking of estrogen 
synthesis by aromatase inhibition in contrast to the weak inhibition of lymphoma growth 
following E2 administration. This might indicate that additional factors than only E2 may be 
involved in the regulation of lymphoma growth. Furthermore, to note is that our studies have 
so far only addressed the role of estrogens and ER in lymphoma progression. Further 
experimental studies are needed to address whether estrogens also affect lymphoma initiation 
as suggested by epidemiological studies e.g. by using mouse models which spontaneously 
develop lymphomas. 
Additional understanding of the mechanisms and target genes involved in estrogen regulation 
of lymphoma growth would be obtained by performing global gene expression profiling. So 
far we have had problems deriving information from microarrays (Affymetrix) using tumor 
material from xenografts, possible due to murine tissue infiltration (cross-reacting probes) or 
due to a very high biological variation within the experimental groups. The prior problem 
might be overcome by purifying MCL tumor cells from the tumor tissue e.g. by purifying 
CD19 positive cells before analysis. An alternative and straighter strategy would be to 
analyze gene expression by RNA sequencing, which can distinguish gene expression in the 
human tumor cells from tumor infiltrating host murine cells. Identifying changes in the 
lymphoma cells of the TME (murine) might also help to evaluate the role of the TME in the 
lymphoma response to estrogens. This is particularly relevant as the response of human 
lymphoma cells in culture to estrogens is week or absent in contrast to a clear tumor growth 
inhibiting effect in vivo. 
4.2 STROMAL CELL-MEDIATED IBRUTINIB RESISTANCE AND STRATEGIES 
TO OVERCOME THIS RESISTANCE 
We have shown that attachment of MCL cells to stromal cells allows MCL cells to escape 
ibrutinib-induced cell apoptosis and help MCL cells to restart proliferation after ibrutinib is 
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removed. This may be due to dysregulated PI3Kα/AKT signaling, which we propose is 
activated by the interaction of the MCL expressed adhesion molecule VLA4 with its 
ligands VCAM1 and fibronectin. Supporting this is that inhibition of PI3Kα or blocking 
VLA4 will overcome stromal cell-mediated ibrutinib resistance of MCL cells. For example, 
the PI3Kα inhibitor BYL719 combined with ibrutinib showed a synergistic effect in 
inducing apoptosis of primary MCL cells and in inhibiting tumor growth in vivo in mice 
grafted with a MCL cell line. 
Only in a limited number of cases of primary or acquired MCL ibrutinib resistance can the 
resistance be explained by mutations of the BTK, the target of ibrutinib. Thus other 
mechanisms for ibrutinib resistance must operate. The TME has long been considered as an 
important component in inducing resistance of tumor cells to cytotoxic drugs, providing a 
protective niche which will allow tumor cell survival and tumor relapse. The mechanism of 
acquired microenvironment-mediated ibrutinib resistance is not well defined and it would 
be a great advancement if the stromal cell-mediated ibrutinib resistance could be overcome. 
Although we have confirmed that VLA4-induced dysregulation of PI3K/AKT signaling is 
an important event for MCL cell to survive, we still are not able to exclude the possibility 
of other signaling pathways involved in mediating the stromal cell-mediated ibrutinib 
resistance. One way to get further insight into the mechanisms involved in stromal cell-
mediated ibrutinib resistance would be to compare differences in gene expression of 
ibrutinib-treated MCL cells in the presence or absence of stromal cells.  This may lead to 
identification of alternative targets that could be targeted in order to overcome ibrutinib 
resistance and more effectively prevent relapse.   
However, as shown by us, detachment of MCL from stromal cells by blocking VLA4 
potentiates the ibrutinib response. This supports that the MCL cell microenvironment, 
especially stromal cells, is a critical factor in mediating ibrutinib resistance. Thus, detaching 
MCL cell from the stroma by blocking adhesion molecular i.e. VLA4, would be an additive 
approach to be considered to overcome ibrutinib resistance. Once MCL cells are mobilized 
to peripheral organs or blood, they will lose adhesion molecular stimulated survival signals 
and regain sensitivity to ibrutinib. In summary, we suggest that combined treatment with 
ibrutinib and a PI3Kα inhibitor, alternatively blocking VLA-4, may be a promising 
therapeutic strategy to overcome stromal cell-mediated ibrutinib resistance in MCL.  
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